Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

The following is a summary of "In-hospital outcomes of cardiogenic shock patients: A propensity score-matched nationwide ...

Mitral TEER in patients with cardiogenic shock was associated with great device success ... language restrictions were undertaken from inception up to the final search day of January 8, 2023, for ...

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...

The recent study by Holger Thiele and colleagues1 offers an extensive meta-analysis on the use of mechanical circulatory support (MCS) in acute myocardial infarction-related cardiogenic shock (AMICS).

Patients with cardiogenic shock supported by Impella CP in an Asian tertiary cardiac center were evaluated for 30‐day post percutaneous ventricular assist device (PVAD) survival after adopting a ...

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic ...

Background: Cardiogenic shock (CS) is the most severe form of heart failure (HF), resulting in high ... supraventricular tachycardia, severe bradycardia, iatrogenesis (medication induced), infections, ...

WINT READ THE FULL WINT RESEARCH REPORT Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company ...

We thank our colleagues for their interest in our Article.1 We agree with Zaoqu Liu and colleagues that in addition to mortality assessment, quality of life and long-term functional outcomes are ...

From the Evans Memorial, Massachusetts Memorial Hospitals, and the Department of Medicine, Boston University School of Medicine. † Assistant professor of medicine, Boston University School of ...

Arrythmias in these patients can be caused by their underlying cardiac disease or by drugs used to treat ... prepare for Phase 3 readiness in cardiogenic shock, we plan to obtain intellectual ...